Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma

NCT00003551 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT00003551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Completed
Start date
August 31, 1998
Completion date
September 30, 2004
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer